Phase 3 Trial Update: Debio 4126 Studied in Acromegaly After Octreotide

On October 23, 2026, a Phase 3 clinical trial update was recorded for a study involving Debio 4126 in participants with acromegaly. The trial, registered as NCT06930625, is titled "A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs." The study enrolls participants who were previously treated with somatostatin analogs, a drug class that includes octreotide. According to the registration, the trial status is currently listed as recruiting. The study is designated as a Phase 3 trial, indicating a later stage of clinical investigation. No results have been posted for this trial as of the date of this update. The event data does not specify efficacy or safety outcomes at this time. This brief reports only the trial's registration status and does not imply any findings. Readers interested in background on octreotide, an approved somatostatin analog, can consult the compound overview for additional context.